title: Psammomabody content and DNA-flow cytometric results as prognostic factors in advanced ovarian carcinoma.
abstract: 138 advanced ovarian serous carcinoma--all FIGO stages III/IV--were investigated by prognostic morphological factors like tumour grading and rate of psammomabody content--subdivided in to serous carcinoma with a high, a moderate and a low rate of psammomabodies and a group of serous carcinoma without psammomabodies. Additionally 91 of these tumours were examined by DNA-flow-cytometry--respectively DNA-ploidy and s-phase-fraction. All prognostic factors were correlated to the overall survival time. The psammomabody content factor is only important if histologically a high or moderate rate of psammomabodies is found in the tumour tissue. Tumours with a low rate of psammomabodies do not differ from serous tumours without psammomabodies. DNA-flow-cytometry is a qualified method to demonstrate a slow tumour growth tendency. The majority of carcinomas with a high rate of psammomabodies is DNA-diploid and has a low -phase-fraction. The overall survival rate for these tumours is much better. Tumour grading--a more subjective method--is also of high value, but there is a certain difficulty in reproducing the results in individual cases. By the combination of the two morphological methods--semiquantitative assessment of psammomabodies and DNA-flow-cytometry--we were able to discover a small group of patients with advanced ovarian cancers who have a favourable prognosis.
authors.affiliation: Department of Gynecological Morphology, University Women's Hospital, Heidelberg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Kühn
authors.forename: M
authors.initials: M
authors.lastname: Kaufmann
authors.forename: G E
authors.initials: GE
authors.lastname: Feichter
authors.forename: H
authors.initials: H
authors.lastname: Schmid
authors.forename: J
authors.initials: J
authors.lastname: Hanke
authors.forename: H H
authors.initials: HH
authors.lastname: Rummel
mesh_terms: D004247:DNA / Q000032:analysis; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis
chemical_list: D004247:DNA